BALTIMORE, 2025-06-13
Cancer’s Sneaky Signals: Detecting Tumors Years Early
Scientists have discovered a way to perhaps detect cancer much earlier than previously possible.
- Genetic material from tumors can be found in the bloodstream up to three years before diagnosis.
- The study used blood samples from the Atherosclerosis Risk in Communities (ARIC) study.
- Early detection could allow for earlier interventions and improved outcomes.
Ever wish you could get a heads-up about health issues? A new study suggests that might be possible when it comes to cancer. Researchers from the Ludwig Center at Johns Hopkins, Johns Hopkins Kimmel Cancer Center, the Johns Hopkins University School of Medicine and the Johns Hopkins Bloomberg School of Public Health have found that genetic clues from tumors can be detected in the blood years before a cancer diagnosis. Specifically, they found these clues up to three years before a diagnosis.
Did you know?-The ARIC study, which provided the blood samples, has been tracking the health of thousands of people since 1987, providing a wealth of data for researchers.
The study, published May 22 in Cancer Revelation, reveals that cancer-derived mutations can be identified in the blood much earlier than previously thought. lead study author Yuxuan Wang, M.D., Ph.D., an assistant professor of oncology at the Johns Hopkins University School of Medicine, noted that “Three years earlier provides time for intervention.The tumors are likely to be much less advanced and more likely to be curable.”
To conduct the research, scientists analyzed plasma samples from the Atherosclerosis Risk in Communities (ARIC) study, a large-scale project funded by the National Institutes of Health. They used advanced sequencing techniques to examine blood samples from 26 participants diagnosed with cancer within six months of sample collection and 26 similar participants who were not diagnosed.
Reader question:-If a blood test can detect cancer mutations years in advance, how might this change preventative care and screening recommendations in the future?
How early can cancer be detected?
Out of 52 participants, eight scored positively on a multicancer early detection (MCED) test. All eight were diagnosed with cancer within four months of blood collection. Researchers examined additional blood samples from six of these individuals, taken 3.1 to 3.5 years before diagnosis. In four of those cases, they could identify tumor-derived mutations in the earlier samples.
“This study shows the promise of MCED tests in detecting cancers very early,and sets the benchmark sensitivities required for their success,” said Bert Vogelstein,M.D., Clayton Professor of Oncology, co-director of the Ludwig Center at Johns Hopkins and a senior author on the study.
Nickolas Papadopoulos, Ph.D., professor of oncology, Ludwig Center investigator and senior author of the study, added that “Detecting cancers years before their clinical diagnosis could help provide management with a more favorable outcome. Of course, we need to determine the appropriate clinical follow-up after a positive test for such cancers.”
The study received funding from several National Institutes of Health grants,the Virginia and D.K. Ludwig fund for Cancer Research, and other organizations.
Unlocking Early Cancer Detection: The Potential of Liquid Biopsies
The discovery of cancer-derived material in the bloodstream, as highlighted by the johns Hopkins study [[2]], opens a new era in cancer detection. This innovative approach, often referred to as a liquid biopsy, moves beyond conventional methods like mammograms and colonoscopies. Liquid biopsies analyze a patient’s blood for signs of cancer, possibly identifying the disease years before symptoms appear.
But how do these liquid biopsies work, and what impact will they have on cancer care?
Deciphering Liquid Biopsies
Liquid biopsies primarily seek circulating tumor DNA (ctDNA). ctDNA fragments – small pieces of genetic material shed by dying cancer cells – can circulate freely in the blood. Researchers analyze ctDNA sequences for specific mutations that signal cancer presence. Advanced sequencing technology used in the ARIC study and many others allow for the identification of even tiny amounts of ctDNA, making early detection feasible.
Besides ctDNA, liquid biopsies can also detect other cancer-related biomarkers. These include circulating tumor cells (CTCs), which are cancer cells that have detached from a tumor and entered the bloodstream, as well as proteins and other substances produced by cancer cells. These biomarkers provide additional clues to cancer’s presence and behavior.
The Benefits of Early detection
The advantages of early cancer detection via blood tests are significant and multifaceted. This is because earlier detection often translates to earlier intervention.
- Increased Treatment Options: When cancer is caught early, more treatment options are available, including surgery, radiation, and targeted therapies, which may not be possible or as effective when the disease is advanced..
- Improved Treatment Outcomes: Early-stage cancers tend to respond better to treatment. This leads to higher survival rates and improved quality of life.
- Reduced Treatment Side Effects: Detecting cancer at its earliest stage often means less aggressive treatment. This, in turn, reduces the side effects associated with harsh therapies like chemotherapy.
- Personalized Cancer Care: ctDNA analysis provides crucial information about a tumor’s genetic makeup. This information helps oncologists personalize treatment plans,focusing on therapies that are most likely to succeed.
The Future of Cancer Screening
The research discussed in the article, alongside ongoing advances, highlights the potential for liquid biopsies to revolutionize cancer screening. These tests are less invasive then traditional methods and can screen for multiple cancers concurrently.
Are liquid biopsies accurate? while promising, today’s liquid biopsy tests aren’t perfect. They can sometimes produce false positives or false negatives. Though, as technology improves, the accuracy of these tests is continuously rising.
How will this affect standard screening procedures? The integration of liquid biopsies into cancer screening could eventually lead to more personalized screening recommendations. People at high risk for certain cancers might undergo blood tests more frequently, supplementing or potentially replacing existing screening methods.
addressing Common Questions
Here are some frequently asked questions about liquid biopsies and their role in cancer care:
What types of cancer can liquid biopsies detect?
Liquid biopsies are gradually becoming available for various types of cancers,including lung cancer,breast cancer,colon cancer,and melanoma. The technology is continually improving,allowing it to identify cancer at its earliest stages,offering patients a greater range of options.
Are liquid biopsies already available?
Yes, some liquid biopsy tests are already available for specific cancers. Though, more research is needed to refine and approve these tests for broader use as a routine screening tool.
Are liquid biopsies covered by insurance?
Coverage varies depending on the specific test,the patient’s insurance plan,and the reason for testing. When possible, patients are advised to check with their insurance provider about coverage before undergoing any liquid biopsy test.
Are liquid biopsies a replacement for other screening tests, like mammograms?
Not necessarily. Liquid biopsies are emerging as a useful supplement to existing screening methods such as mammograms, colonoscopies, and other imaging technologies. Until the data convincingly demonstrates liquid biopsies are as effective as current screening tools, these tools should also be used as appropriate.
The information provided is for educational purposes only and does not substitute professional medical advice. Always discuss your concerns with a qualified healthcare provider.
Table of Contents
